Oral Methotrexate for Recurrent Brain Tumors in Children: A Pediatric Oncology Group Study
作者:
Arlynn,
Mulne Jonathan,
Ducore Roy,
Elterman Henry,
Friedman Jeffrey,
Krischer Larry,
Kun Jonathan,
Shuster Richard,
期刊:
Journal of Pediatric Hematology/Oncology
(OVID Available online 2000)
卷期:
Volume 22,
issue 1
页码: 41-44
ISSN:1077-4114
年代: 2000
出版商: OVID
关键词: Brain tumor;Phase II study;Methotrexate
数据来源: OVID
摘要:
Purpose:Children with recurrent or progressive central nervous system (CNS) tumors have an unfavorable prognosis. Based on Pediatric Oncology Group (POG) institutional pilot data, low-dose oral methotrexate (MTX) was studied.Methods:Eight dosages of MTX 7.5 mg/m2every 6 hours were administered on a weekly schedule for as long as 18 months. Patients in six different brain tumor strata were accrued.Results:The response rates (complete or partial responses) were as follows: astrocytoma 2 of 10, malignant glioma 1 of 19, medulloblastoma 0 of 18, brainstem tumor 0 of 12, ependymoma 1 of 7, and miscellaneous histologic types 0 of 12. The main toxicities, mucositis, myelosuppression, and hepatic transaminase elevation were considered tolerable.Conclusion:Low-dose oral MTX showed no significant activity against malignant glioma, medulloblastoma, brainstem tumors, and miscellaneous histologic types. Indeterminate but low response rates were observed in children with astrocytoma and ependymoma. This regimen will not be recommended for front-line therapy.
返 回